Insider Trading disclosures for NewAmsterdam Pharma Company NV

The latest disclosure was made by Douglas F. Kling in NewAmsterdam Pharma Company NV where a trade of 88,112 Ordinary Shares done was reported to US exchanges on March 17, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	17 Mar 2025	88,112	132,112	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share.	17 Mar 2025	11,888	144,000	-	10	118,880	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	17 Mar 2025	88,112	47,251	-		-	Option (right to buy)
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	17 Mar 2025	11,888	650,930	-		-	Option (right to buy)
Douglas F. Kling	Chief Operating Officer	Sale of securities on an exchange or to another person at price $ 0.00 per share.	17 Mar 2025	100,000	44,000	-		-	Ordinary Shares
Louise Kooij	Chief Accounting Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	04 Mar 2025	150,000	165,000	-		-	Ordinary Shares
Louise Kooij	Chief Accounting Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	04 Mar 2025	150,000	18,073	-		-	Option (right to buy)
Louise Kooij	Chief Accounting Officer	Sale of securities on an exchange or to another person at price $ 20.37 per share.	04 Mar 2025	150,000	15,000	-	20.4	3,055,500	Ordinary Shares
James N. Topper	Director	Purchase of securities on an exchange or from another person at price $ 21.02 per share.	04 Mar 2025	4,005	3,012,434	-	21.0	84,203	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	18 Feb 2025	90,782	134,782	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Sale of securities on an exchange or to another person at price $ 0.00 per share.	18 Feb 2025	90,782	44,000	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	18 Feb 2025	9,218	53,218	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Sale of securities on an exchange or to another person at price $ 0.00 per share.	18 Feb 2025	9,218	44,000	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	18 Feb 2025	90,782	135,363	-		-	Option (right to buy)
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	18 Feb 2025	9,218	126,145	-		-	Option (right to buy)
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	29 Jan 2025	56,863	239,723	-		-	Option (right to buy)
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	29 Jan 2025	13,578	226,145	-		-	Option (right to buy)
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	29 Jan 2025	56,863	100,863	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Sale of securities on an exchange or to another person at price $ 0.00 per share.	29 Jan 2025	56,863	44,000	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Sale of securities on an exchange or to another person at price $ 0.00 per share.	29 Jan 2025	8,914	44,000	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Sale of securities on an exchange or to another person at price $ 0.00 per share.	29 Jan 2025	4,664	52,914	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	29 Jan 2025	13,578	57,578	-		-	Ordinary Shares
Ian Somaiya	Chief Financial Officer	Sale of securities on an exchange or to another person at price $ 0.00 per share.	27 Jan 2025	33,679	51,304	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	27 Jan 2025	104,174	321,971	-		-	Option (right to buy)
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	27 Jan 2025	25,385	296,586	-		-	Option (right to buy)
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	27 Jan 2025	104,174	148,174	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Sale of securities on an exchange or to another person at price $ 0.00 per share.	27 Jan 2025	80,359	67,815	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Sale of securities on an exchange or to another person at price $ 0.00 per share.	27 Jan 2025	23,815	44,000	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	27 Jan 2025	25,385	69,385	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Sale of securities on an exchange or to another person at price $ 0.00 per share.	27 Jan 2025	20,237	49,148	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Sale of securities on an exchange or to another person at price $ 0.00 per share.	27 Jan 2025	5,148	44,000	-		-	Ordinary Shares
Ian Somaiya	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	27 Jan 2025	14,900	762,814	-		-	Option (Right to Buy)
Ian Somaiya	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.26 per share.	27 Jan 2025	14,900	52,900	-	9.3	137,974	Ordinary Shares
Ian Somaiya	Chief Financial Officer	Sale of securities on an exchange or to another person at price $ 0.00 per share.	27 Jan 2025	11,495	41,405	-		-	Ordinary Shares
Ian Somaiya	Chief Financial Officer	Sale of securities on an exchange or to another person at price $ 0.00 per share.	27 Jan 2025	3,405	38,000	-		-	Ordinary Shares
Ian Somaiya	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share.	27 Jan 2025	46,983	777,714	-		-	Option (Right to Buy)
Ian Somaiya	Chief Financial Officer	Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.26 per share.	27 Jan 2025	46,983	84,983	-	9.3	435,063	Ordinary Shares
Ian Somaiya	Chief Financial Officer	Sale of securities on an exchange or to another person at price $ 0.00 per share.	27 Jan 2025	13,304	38,000	-		-	Ordinary Shares
Ian Somaiya	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jan 2025	38,000	38,000	-		-	Ordinary Shares
Johannes Jacob Pieter Kastelein	Director, Chief Scientific Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jan 2025	34,000	34,000	-		-	Ordinary Shares
Juliette Audet	Chief Business Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jan 2025	14,000	15,104	-		-	Ordinary Shares
Louise Kooij	Chief Accounting Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jan 2025	15,000	15,000	-		-	Ordinary Shares
Douglas F. Kling	Chief Operating Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jan 2025	44,000	44,000	-		-	Ordinary Shares
William B.J. Jones	Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jan 2025	43,000	43,000	-		-	Ordinary Shares
John W. Smither	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Jan 2025	32,500	32,500	-		-	Option (right to buy)
Janneke van der Kamp	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Jan 2025	6,960	6,960	-		-	Ordinary Shares
Michael Harvey Davidson	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Jan 2025	123,529	123,529	-		-	Ordinary Shares
Janneke van der Kamp	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Jan 2025	32,500	32,500	-		-	Option (right to buy)
Michael Harvey Davidson	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Jan 2025	670,467	670,467	-		-	Option (right to buy)
Louis G. Lange	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	06 Jan 2025	6,960	6,960	-		-	Ordinary Shares

Showing 1 to 50 of 86 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

48.52% Gain from 52W Low

Insider Trading disclosures for NewAmsterdam Pharma Company NV

The latest disclosure was made by Douglas F. Kling in NewAmsterdam Pharma Company NV where a trade of 88,112 Ordinary Shares done was reported to US exchanges on March 17, 2025.

Screeners based on Insider Trading and SAST parameters